Labeling Requirements for Human Prescription Drug and Biological Products
No material or nonsubstantive change to a currently approved collection
No
Regular
02/11/2022
Requested
Previously Approved
01/31/2025
01/31/2025
433,323
432,929
1,913,864
1,912,106
129,150
0
The information collection supports agency regulations governing the content and format of labeling for human prescription drug and biological products. Respondents to the collection are sponsors of new drug and biological product applications.
For efficiency of agency operations, we are requesting to consolidate the related information collection activity and account for burden we attribute to the recommendations found in the referenced guidance document, as well as burden associated with waiver requests from bar code requirements in 21 CFR part 201. Accordingly, we have adjusted the estimated burden in control number 0910-0572 by 394 responses, 1,758 hours, and $129,150 cost annually to reflect these changes. Upon approval of this request, we intend to discontinue the collections of information currently approved under OMB control numbers 0910-0734, 0910-0537 and 0910-0670.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.